



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 12:41
Last Report Issued 09/10/2014 08:24

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2626B
Patient ID 2626B
Chain 14002611
Age Not Given DOB Not Given
Gender Not Given
Workorder 14002611
Received 09/09/2014 10:31

Sample ID 14002611-001
Matrix Blood
Patient Name 2626B
Patient ID 2626B
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

2626B Bath Salts Panel, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Methylone None Detected ng/mL 5.0
Synonym(s): 3,4-methylenedioxy-N-methylcathinone; bk-MDMA

Methylone is a methylenedioxy beta keto amphetamine, or
cathinone stimulant drug. It is the beta-keto analog of
MDMA. Its use has been linked to the
popular 'Designer Drug' movement, and may be present in
products sold as 'Legal High' or 'Bath Salts' for
recreational purposes. Methylone acts as an inhibitor
of dopamine, norepinephrine, and serotonin reuptake and
may have stimulating effects on the central nervous
system. The drug is usually taken orally, but can also
be insufflated or vaporized.

Euphoria, agitation, sweating, nausea, vomiting,
dilated pupils, seizures, hyponatremia and confusion
were reported in two cases after the use of bath salt
products found to contain methylone. Other substances
may have been present.

Four fatalities attributed to this drug had methylone
heart blood concentrations of 60 - 1100 ng/mL;

Results for sample 14002611-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 14002611-001
Matrix Blood
Patient Name 2626B
Patient ID 2626B

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains data for Mephedrone and alpha-PVP.

Results for sample 14002611-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 14002611-001
Matrix Blood
Patient Name 2626B
Patient ID 2626B

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains two rows for Pentedrone and MDPV with detailed analysis and comments.

Results for sample 14002611-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 14002611-001
Matrix Blood
Patient Name 2626B
Patient ID 2626B

Collect Dt/Tm Not Given
Source Not Given

Table header with columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

orally, but can also be insufflated or vaporized.

Blood concentrations in 17 fatalities were 10 - 5000 ng/mL. Blood concentrations in 9 cases of drivers exhibiting signs of impairment were 6 - 360 ng/ml; other impairing drugs were often found in conjunction with MDPV.

Methoxetamine None Detected ng/mL 2.0

Synonym(s): 2-MeO-Oxo-PC; MXE

Methoxetamine is a psychoactive compound that is structurally related to ketamine and reported to have similar effects. Ketamine is a DEA Schedule III rapidly acting general anesthetic that is chemically related to phencyclidine (PCP). The effects of ketamine include profound analgesia, normal or enhanced skeletal muscle tone and cardiovascular and respiratory stimulation. Reactions manifested by hallucinations, delirium, irrational behavior and/or dream-like states may be seen with use of ketamine and, presumably, methoxetamine. The use of methoxetamine has been linked to the popular 'Designer Drug' movement and this substance may be present in products sold as 'Legal Highs' or 'Bath Salts' for recreational purposes.

Blood concentrations of 130 – 490 ng/g (approximately 130 – 510 ng/mL) have been reported following acute ingestion of methoxetamine. In one fatality a concentration of 8600 ng/g (approximately 9000 ng/mL) was reported.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.